Elanco Animal Health (NYSE:ELAN) Releases Q3 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its third quarter earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $0.09-0.14 for the period, compared to the consensus estimate of $0.19. The company issued revenue guidance of $1.02-1.05 billion, compared to the consensus revenue estimate of $1.07 billion. Elanco Animal Health also updated its FY 2024 guidance to 0.880-0.960 EPS.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of research reports. Barclays cut their target price on shares of Elanco Animal Health from $23.00 to $21.00 and set an overweight rating on the stock in a research note on Friday, June 28th. Piper Sandler decreased their price objective on shares of Elanco Animal Health from $19.00 to $16.00 and set a neutral rating for the company in a research report on Monday, July 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health has an average rating of Moderate Buy and an average price target of $17.57.

Elanco Animal Health Stock Up 0.4 %

ELAN stock traded up $0.05 during mid-day trading on Friday, hitting $13.04. 4,922,213 shares of the company were exchanged, compared to its average volume of 4,884,853. The company has a market capitalization of $6.44 billion, a PE ratio of -4.92, a price-to-earnings-growth ratio of 1.27 and a beta of 1.42. The firm has a fifty day simple moving average of $15.02 and a 200 day simple moving average of $15.38. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.95. Elanco Animal Health has a twelve month low of $8.52 and a twelve month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The firm had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same period in the previous year, the company earned $0.18 earnings per share. Elanco Animal Health’s quarterly revenue was up 12.0% on a year-over-year basis. On average, research analysts forecast that Elanco Animal Health will post 0.93 earnings per share for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director William F. Doyle acquired 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The shares were purchased at an average price of $16.98 per share, for a total transaction of $254,700.00. Following the completion of the purchase, the director now directly owns 76,330 shares in the company, valued at $1,296,083.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.57% of the stock is owned by insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.